| Essential Hypertension
Edarbi vs Edarbyclor
Side-by-side clinical, coverage, and cost comparison for essential hypertension.Deep comparison between: Edarbi vs Edarbyclor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEdarbyclor has a higher rate of injection site reactions vs Edarbi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Edarbyclor but not Edarbi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edarbi
Edarbyclor
At A Glance
Oral
Once daily
Angiotensin II receptor blocker
Oral
Once daily
ARB / thiazide-like diuretic
Indications
- Essential Hypertension
- Essential Hypertension
Dosing
Essential Hypertension 80 mg orally once daily; consider a starting dose of 40 mg for patients treated with high doses of diuretics. May be administered with or without food and with other antihypertensive agents.
Essential Hypertension Starting dose 40/12.5 mg orally once daily; may increase to 40/25 mg after 2 to 4 weeks as needed to achieve blood pressure goals; maximum dose 40/25 mg.
Contraindications
- Coadministration of aliskiren-containing products in patients with diabetes
- Anuria
- Coadministration of aliskiren-containing products in patients with diabetes
Adverse Reactions
Most common diarrhea, nausea, asthenia, fatigue, muscle spasm, dizziness, dizziness postural, cough
Postmarketing rash, pruritus, angioedema
Most common (>=2%) Dizziness, fatigue
Serious Hypotension, syncope, increased serum creatinine, hypokalemia, hyperuricemia
Postmarketing Loss of consciousness, pruritus, angioedema
Pharmacology
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively blocks binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, inhibiting vasoconstriction and aldosterone secretion; azilsartan medoxomil is a prodrug rapidly converted to azilsartan by esterases during gastrointestinal absorption.
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to inhibit vasoconstriction and aldosterone secretion; chlorthalidone is a thiazide-like diuretic that inhibits NaCl reabsorption in the distal renal tubule, reducing extracellular fluid volume and blood pressure via complementary mechanisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edarbi
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (7/12) · Qty limit (11/12)
Edarbyclor
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (12/12)
UnitedHealthcare
Edarbi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Edarbyclor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Edarbi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Edarbyclor
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Edarbi.
No savings programs available for Edarbyclor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdarbiView full Edarbi profile
EdarbyclorView full Edarbyclor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.